Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Bifidobacterium breve Bb-18 and Reduced Inflammation

Research synthesisLow evidenceMixed effect size4 studies · 4 beneficial · 0 neutral · 0 harmful

Across 4 studies, all reported beneficial effects of Bifidobacterium breve Bb-18 on reducing inflammation, with effect sizes ranging from small to moderate. The highest-quality evidence (a meta-analysis with 3,390 participants) showed small beneficial effects, including reductions in high-sensitivity C-reactive protein and tumor necrosis factor alpha. Most studies did not report specific doses, duration, or form, and no findings reached statistical significance.

  • Studied populations: subjects with type 2 diabetes mellitus, adults with gestational diabetes mellitus, healthy adults

Caveats: Evidence base is small (only 4 studies) — conclusions should be considered preliminary. Many of the included studies did not reach statistical significance — effect may be smaller than the predominant direction suggests. Available evidence is overwhelmingly positive — clinical literature in this area is subject to publication bias (null-result studies are less likely to be published or indexed). Doses, forms, and study durations were inconsistently reported, limiting specificity of recommendations.

Generated May 12, 2026
4 of 4 papers
Back to top